Sodium polystyrene sulfonate
As of the edition of 20 October 2026, Sodium polystyrene sulfonate is a small molecule: marketed, first approved in 1961 (CA).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2007
- Kind
- Small molecule
- Brand name
- Kayexalate
- First approved
- 31 December 1961 (CA)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- FRESENIUS MEDICAL CARE NEPHROLOGICA DEUTSCHLAND; 3 holders in all
- Registered trials
- 3, 1 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Hormones; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 3 |